| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/08/2023 | 53.3% | HC Wainwright & Co. | → $60 | Reiterates | Buy → Buy |
| 08/30/2023 | 53.3% | HC Wainwright & Co. | → $60 | Reiterates | Buy → Buy |
| 08/15/2023 | 53.3% | HC Wainwright & Co. | $61 → $60 | Maintains | Buy |
| 08/10/2023 | 55.85% | Morgan Stanley | $60 → $61 | Maintains | Overweight |
| 07/24/2023 | 55.85% | HC Wainwright & Co. | → $61 | Initiates Coverage On | → Buy |
| 07/24/2023 | 14.97% | Goldman Sachs | $43 → $45 | Downgrades | Buy → Neutral |
| 05/10/2023 | 68.63% | JMP Securities | → $66 | Reiterates | → Market Outperform |
| 05/10/2023 | 53.3% | Morgan Stanley | $64 → $60 | Maintains | Overweight |
| 05/10/2023 | 17.53% | Piper Sandler | → $46 | Upgrades | Neutral → Overweight |
| 03/27/2023 | 48.19% | Berenberg | → $58 | Reinstates | → Buy |
| 03/17/2023 | 22.64% | Wells Fargo | $55 → $48 | Maintains | Overweight |
| 03/16/2023 | 7.31% | SVB Leerink | → $42 | Downgrades | Outperform → Market Perform |
| 03/16/2023 | 40.52% | Wells Fargo | $65 → $55 | Maintains | Overweight |
| 03/06/2023 | 63.52% | Morgan Stanley | $65 → $64 | Maintains | Overweight |
| 02/23/2023 | 32.86% | JP Morgan | $54 → $52 | Maintains | Overweight |
| 02/22/2023 | 68.63% | JMP Securities | $62 → $66 | Reiterates | → Market Outperform |
| 01/11/2023 | 55.85% | SVB Leerink | $62 → $61 | Maintains | Outperform |
| 12/21/2022 | 66.07% | Morgan Stanley | $53 → $65 | Maintains | Overweight |
| 12/08/2022 | 73.74% | Benchmark | $55 → $68 | Maintains | Buy |
| 11/28/2022 | 66.07% | Wells Fargo | → $65 | Initiates Coverage On | → Overweight |
| 11/22/2022 | 37.97% | JP Morgan | $53 → $54 | Maintains | Overweight |
| 11/14/2022 | 58.41% | SVB Leerink | $52 → $62 | Maintains | Outperform |
| 11/09/2022 | 58.41% | JMP Securities | $60 → $62 | Maintains | Market Outperform |
| 09/09/2022 | 27.75% | Morgan Stanley | → $50 | Initiates Coverage On | → Overweight |
| 05/26/2022 | 53.3% | Goldman Sachs | $48 → $60 | Maintains | Buy |
| 05/11/2022 | 48.19% | JMP Securities | $55 → $58 | Maintains | Market Outperform |
| 11/24/2021 | 48.19% | Wells Fargo | $60 → $58 | Maintains | Overweight |
| 11/03/2021 | 40.52% | JMP Securities | $52 → $55 | Maintains | Market Outperform |
| 11/03/2021 | 22.64% | SVB Leerink | $50 → $48 | Maintains | Outperform |
| 06/14/2021 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 05/17/2021 | 43.08% | SVB Leerink | → $56 | Initiates Coverage On | → Outperform |
| 05/11/2021 | 22.64% | Piper Sandler | $50 → $48 | Downgrades | Overweight → Neutral |
| 12/17/2020 | 27.75% | Berenberg | → $50 | Initiates Coverage On | → Buy |
| 11/16/2020 | 53.3% | Wells Fargo | $39 → $60 | Maintains | Overweight |
| 07/02/2020 | -20.8% | Piper Sandler | $28 → $31 | Maintains | Overweight |
| 07/01/2020 | -0.36% | Benchmark | → $39 | Initiates Coverage On | → Buy |
| 06/15/2020 | -33.57% | Citigroup | $18 → $26 | Maintains | Neutral |
| 05/19/2020 | -31.02% | Canaccord Genuity | $23 → $27 | Maintains | Buy |
| 05/12/2020 | -13.13% | JMP Securities | $24 → $34 | Maintains | Market Outperform |
| 05/12/2020 | -41.24% | JP Morgan | $22 → $23 | Maintains | Overweight |
| 05/12/2020 | -10.58% | BMO Capital | $27 → $35 | Maintains | Outperform |
| 05/04/2020 | -0.36% | Cantor Fitzgerald | $35 → $39 | Reiterates | → Overweight |
| 02/25/2020 | -48.9% | Barclays | $16 → $20 | Maintains | Equal-Weight |
| 02/25/2020 | -43.79% | JP Morgan | $24 → $22 | Maintains | Overweight |
| 02/05/2020 | -31.02% | Piper Sandler | $18 → $27 | Upgrades | Neutral → Overweight |
| 01/27/2020 | -10.58% | Cantor Fitzgerald | $27 → $35 | Maintains | Overweight |
| 01/09/2020 | -38.68% | BMO Capital | $17 → $24 | Upgrades | Market Perform → Outperform |
| 01/08/2020 | -38.68% | Goldman Sachs | → $24 | Initiates Coverage On | → Buy |
| 11/20/2019 | -31.02% | Cantor Fitzgerald | $26 → $27 | Reiterates | → Overweight |
| 11/13/2019 | -56.57% | BMO Capital | $16 → $17 | Maintains | Market Perform |
| 11/13/2019 | -41.24% | JP Morgan | $20 → $23 | Maintains | Overweight |
| 11/05/2019 | -59.12% | Barclays | $17 → $16 | Upgrades | Underweight → Equal-Weight |
What is the target price for Halozyme Therapeutics (HALO)?
The latest price target for Halozyme Therapeutics (NASDAQ: HALO) was reported by HC Wainwright & Co. on September 8, 2023. The analyst firm set a price target for $60.00 expecting HALO to rise to within 12 months (a possible 53.30% upside). 24 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Halozyme Therapeutics (HALO)?
The latest analyst rating for Halozyme Therapeutics (NASDAQ: HALO) was provided by HC Wainwright & Co., and Halozyme Therapeutics reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Halozyme Therapeutics (HALO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Halozyme Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Halozyme Therapeutics was filed on September 8, 2023 so you should expect the next rating to be made available sometime around September 8, 2024.
Is the Analyst Rating Halozyme Therapeutics (HALO) correct?
While ratings are subjective and will change, the latest Halozyme Therapeutics (HALO) rating was a reiterated with a price target of $0.00 to $60.00. The current price Halozyme Therapeutics (HALO) is trading at is $39.14, which is within the analyst's predicted range.